Ernexa Therapeutics Inc. Common Stock (ERNA) is a publicly traded Healthcare sector company. As of May 20, 2026, ERNA trades at $11.24 with a market cap of $14.29M and a P/E ratio of -4.92. ERNA moved +0.00% today. Year to date, ERNA is -60.52%; over the trailing twelve months it is -86.72%. Its 52-week range spans $3.18 to $558.75. Analyst consensus is buy with an average price target of $30.00. Rallies surfaces ERNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Ernexa’s ERNA-101 Achieves 100% Tumor Elimination in Preclinical Ovarian Models: Ernexa Therapeutics unveiled preclinical data showing its ERNA-101 candidate achieved complete tumor elimination and 100% long-term survival in ovarian cancer models when combined with PD-1 blockade. The company highlighted its off-the-shelf induced mesenchymal stem cell platform designed to address immunologically cold tumors and scale manufacturing for advanced cancer therapy.
| Metric | Value |
|---|---|
| Price | $11.24 |
| Market Cap | $14.29M |
| P/E Ratio | -4.92 |
| EPS | $-2.24 |
| Dividend Yield | 0.00% |
| 52-Week High | $558.75 |
| 52-Week Low | $3.18 |
| Volume | 51.55K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-14.08M |
| Gross Margin | 0.00% |
1 analysts cover ERNA: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $30.00.